Researchers from the Hunter Holmes McGuire VA Medical Center, Richmond, VA, and the Department of Rheumatic and Immunologic Diseases, Orthopedics and Rheumatology Institute, Cleveland Clinic, OH, have recently released results from a clinical trial that evaluated the use of ambrisentan, a selective endothelin type A receptor antagonist,…
News
The Assistance Publique – Hôpitaux de Paris is collaborating with Actelion Pharmaceutics on a study testing the efficacy, safety and tolerability of bosentan in patients with scleroderma renal crisis on renal function (ClinicalTrials.gov Identifier: NCT01241383). Systemic sclerosis (SSc) is an auto-immune disorder that causes excessive collagen deposition,…
Yuval Cohen (PhD), Chief Executive of Corbus Pharmaceuticals A new proposed treatment for scleroderma will soon be in Phase 2 clinical trials. Corbus Pharmaceuticals, based in Norwood, Massachusetts, recently received clearance from the FDA for their investigational new drug (IND),…
Cytori Therapeutics, Inc. recently announced an FDA approval that will allow them to expand the number of sites in the United States from 12 to 20 centers where the company’s Scleroderma clinical trials are currently being conducted. The STAR study was approved by the FDA in January 2015 as an 80-patient…
Cytori Therapeutics, Inc. recently announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has given a positive opinion concerning Cytori’s submission for an orphan drug designation for ECCS-50, the company’s experimental Scleroderma therapeutic, which is based on stromal vascular fraction cells, from adipose tissue and derived from Celution® System,…
A recent study published in the journal Arthritis Research & Therapy analyzed different prediction algorithms for the efficient diagnosis of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis. The study is entitled “A comparison of the predictive accuracy of three screening models…
Richard Burt, MD, of Northwestern University is looking to harness the power of autologous, patient-derived stem cells for the treatment of systemic sclerosis. His previous work in a clinical trial with scleroderma motivated a new phase 3 clinical trial, entitled “…
New research on musculoskeletal ultrasound (MSUS) hand features in systemic sclerosis (SSc) or scleroderma and rheumatoid arthritis (RA) entitled “A comparative study between ultrasonographic hand features in systemic sclerosis and rheumatoid arthritis patients: Relation to disease activity, clinical and radiological findings” was recently published in the…
In a recent study entitled “Scleroderma renal crisis,” the authors summarize the most recent findings related to scleroderma renal crisis, a serious but treatable complication of systemic sclerosis. The study was published in the journal Seminars in Arthritis and Rheumatism. Scleroderma (or systemic…
Researchers at Cairo University in Egypt recently published in The Egyptian Rheumatologist journal their findings on auditory dysfunction observed in systemic sclerosis patients. The study is entitled “Otolith function assessment in patients with systemic sclerosis.” Systemic sclerosis, also known as…
Recent Posts
- New study flags existing medications as possible scleroderma treatments
- Anti-CD146 antibodies may signal occupational exposure in SSc: Study
- New SSc drug safely cuts Raynaud’s attack duration, eases symptoms
- Carbon dioxide hand baths may help in SSc-related Raynaud’s, study finds
- More SSc-ILD patients receive early treatment, new study finds
- CD13 levels elevated in scleroderma, but biomarker value unclear
- New lab findings support development of stem cell treatments for SSc-ILD
- Type of immune cell may be key driver of scleroderma scarring: Study
- Abnormal fatty acid metabolism may play role in scleroderma: Analysis
- Cosmetic laser therapy could be repurposed for localized scleroderma